If you or someone that you care about is receiving treatment for cancer, you want to make sure that the medical professionals that they are working with have all of the information available to help them make the right care decisions. This is what Eric Lefkofsky is hoping to do with his company Tempus which provides new data solutions for cancer care. The company was co-founded in 2015 by Eric Lefkofsky after witnessing problems that the health care industry had when it came to patient information. He was hoping that something better was in the works but when he realized there wasn’t, he set about to make something better himself. With the background he has had with other disruptive companies, Eric Lefkofsky was able to find a strong team to help with the process.
Helping those with cancer through Tempus is not the only way that Eric Lefkofsky strives to give back to the world. In fact, he and his wife are so passionate about philanthropy that they created the Lefkofsky Family Foundation. This non-profit organization strives to help people in and around Chicago with a focus on health care, education, and arts for children. As a Member of the Board of Directors for Lurie Children’s Hospital, he is able to play a strong part in how children are treated medically. He is involved with several other organizations throughout Chicago such as the Art Institute of Chicago and the Steppenwolf Theatre Company as a member of their Boards of Trustees.
Cancer care is changing along with the rest of the world of health and it’s time for medical records to catch up. In addition to making the information stored more indexed to be easier to access and reference, Tempus also includes ways to enter in information for genetic testing. These genetic tests can be used in many different ways to ensure a better outcome for the patient through customized treatment and also through compiling data for new treatments. Eric Lefkofsky believes that by collecting this information, they will also potentially be able to prevent certain diseases from developing if patients carry specific genetic markers.